HMGB1 in Hormone-Related Cancer: a Potential Therapeutic Target

被引：27

作者：

Srinivasan, Madhuwanti ^{[1
]}

Banerjee, Souresh ^{[1
]}

Palmer, Allison ^{[1
]}

Zheng, Guoxing ^{[1
]}

Chen, Aoshuang ^{[1
]}

Bosland, Maarten C. ^{[2
]}

Kajdacsy-Balla, Andr ^{[2
]}

Kalyanasundaram, Ramaswamy ^{[1
]}

Munirathinam, Gnanasekar ^{[1
,3
]}

机构：

[1] Univ Illinois, Coll Med, Dept Biomed Sci, Rockford, IL 61107 USA

[2] Univ Illinois, Dept Pathol, Chicago, IL USA

[3] Univ Illinois, Ctr Canc, Chicago, IL USA

来源：

HORMONES & CANCER | 2014年 / 5卷 / 03期

关键词：

MOBILITY GROUP BOX-1; END-PRODUCTS RAGE; DNA-BINDING; CELL-DEATH; PROGESTERONE-RECEPTOR; CHROMATIN PROTEINS; MESSENGER-RNA; LETHAL SEPSIS; CALF-THYMUS; BETA-CELLS;

D O I：

10.1007/s12672-014-0175-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

High-mobility group box 1 (HMGB1) is a dynamic nuclear protein participating in transcription, chromatin remodelling, and DNA recombination and repair processes. Accumulating evidence indicates that its function now extends beyond the nucleus, notably its extracellular role in inflammation. HMGB1 is implicated as a late mediator of sepsis and is also believed to promote atherosclerosis and other inflammatory diseases such as rheumatoid arthritis and systemic lupus erythematosus. Interestingly, deregulation of HMGB1 is shown to be associated with the hallmarks of cancer development. Moreover, several clinical studies have shown that HMGB1 is a promising biomarker for a variety of cancer types. In this review, we provide novel insights into the role and mechanisms of HMGB1, in particular, to hormone-related cancers and its potential to serve as a therapeutic target.

引用

页码：127 / 139

页数：13

共 50 条

[41] HMGB1 as biomarker and drug target
Venereau, Emilie
De Leo, Federica
Mezzapelle, Rosanna
Careccia, Giorgia
Musco, Giovanna
Bianchi, Marco E.
PHARMACOLOGICAL RESEARCH, 2016, 111 : 534 - 544
[42] Therapeutic Potential of Targeting the HMGB1/RAGE Axis in Inflammatory Diseases
Singh, Harbinder
Agrawal, Devendra K.
MOLECULES, 2022, 27 (21):
[43] Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease
Liu, Tongtong
Li, Qian
Jin, Qi
Yang, Liping
Mao, Huimin
Qu, Peng
Guo, Jing
Zhang, Bo
Ma, Fang
Wang, Yuyang
Peng, Liang
Li, Ping
Zhan, Yongli
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2023, 19 (15): : 5020 - 5035
[44] Use of single-point mutated HMGB1 box a variants as therapeutic agents in HMGB1 and rage related pathologies
Lorenzetto, Chiara
Fumero, Silvano
Barone, Domenico
Traversa, Silvio
Guyon, Thierry
Borrelly, Gilles
INFLAMMATION RESEARCH, 2007, 56 : S190 - S190
[45] HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis
Andersson, U
Tracey, KJ
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2004, 30 (03) : 627 - +
[46] Bench to bedside: HMGB1 - A novel proinflammatory cytokine and potential therapeutic target for septic patients in the emergency department
Sama, AE
D'Amore, J
Ward, MF
Chen, GQ
Wang, HC
ACADEMIC EMERGENCY MEDICINE, 2004, 11 (08) : 867 - 873
[47] HMGB1 in inflammation and cancer
Shumin Wang
Yi Zhang
Journal of Hematology & Oncology, 13
[48] The roles of HMGB1 related angiogenesis and lymphangiogenesis in oral cancer
Sasahira, Tomonori
Yamamoto, Kazuhiko
Kurihara, Miyako
Bhawal, Ujjal K.
Chihara, Yoshitomo
Kirita, Tadaaki
Kuniyasu, Hiroki
ONCOLOGY REVIEWS, 2011, 5 (01) : 49 - 55
[49] Design of a selected single-point mutated HMGB1 box a variant as therapeutic agent in HMGB1 and RAGE related pathologies
Lorenzetto, C.
Barone, D.
Borrelly, G.
Drittanti, L.
Guyon, T.
Morena, S.
Oderda, C.
Odrzywol, K.
Traversa, S.
Fumero, S.
PROCEEDINGS OF THE 7TH WORLD CONGRESS ON TRAUMA, SHOCK, INFLAMMATION AND SEPSIS, 2007, : 87 - +
[50] HMGB1 in inflammation and cancer
Wang, Shumin
Zhang, Yi
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)

← 1 2 3 4 5 →